Trial Profile
Phase 0 Study Aiming at Identifying Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 08 Oct 2017
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Colon cancer
- Focus Biomarker; Pharmacodynamics
- 29 Sep 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 May 2016 New trial record